Slow Parkinson degeneration using Dserine
- Trial ID
- NCT07312110
- Official Title
- D-SPARK: A Randomized Double Blind Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression
- Goal
- Slow Parkinson degeneration using Dserine
- Phase
- PHASE2
- Status
- RECRUITING
- Sponsor
- Haukeland University Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 100 participants
- Conditions
- Parkinson s Disease, Parkinson Disease (PD)
- Interventions
- D-serine, Placebo
Summary For Families
The goal is to find out whether D-serine can slow Parkinson's progression by boosting glutamate-driven synaptic function and helping protect neurons, not just treating symptoms. D-serine is a natural co-agonist at NMDA receptors, it enhances NMDA receptor signaling to support synaptic plasticity and neuronal health, and it will be tested against placebo while participants stay on stable Parkinson's meds. The trial seeks people 40 to 80 years old diagnosed within the last 5 years with DaTscan-confirmed PD and Hoehn and Yahr under 3, on stable symptomatic treatment; dementia, atypical parkinsonism, significant kidney disease, recent D-serine use, and other serious medical or psychiatric issues are exclusions.
Locations
- Nevro Arendal Soerlandsklinikken, Arendal, Agder, Norway
- Akershus University Hospital, Lørenskog, Akershus, Norway
- Vestre Viken Hospital, Drammen, Buskerud, Norway
- Molde Hospital, Molde, Møre og Romsdal, Norway
- Bodø Hospital (Nordland Hospital), Bodø, Nordland, Norway
- Oslo University Hospital, Oslo, Oslo, Norway
- Haugesund Hospital, Haugesund, Rogaland, Norway
- University Hospital of North Norway, Tromsø, Troms, Norway
- Haukeland University Hospital, Bergen, Vestland, Norway
- Førde Hospital, Førde, Vestland, Norway
- Østfold Hospital, Sarpsborg, Østfold fylke, Norway
Frequently Asked Questions
- What is this trial testing?
- This trial is studying D-serine. The goal is to find out whether D-serine can slow Parkinson's progression by boosting glutamate-driven synaptic function and helping protect neurons, not just treating symptoms. D-serine is a natural co-agonist at NMDA receptors, it enhances NMDA receptor signaling to support synaptic plasticity and neuronal health, and it will be tested against placebo while participants stay on stable Parkinson's meds. The trial seeks people 40 to 80 years old diagnosed within the last 5 years with DaTscan-confirmed PD and Hoehn and Yahr under 3, on stable symptomatic treatment; dementia, atypical parkinsonism, significant kidney disease, recent D-serine use, and other serious medical or psychiatric issues are exclusions.
- Who can participate?
- Participants must be between 40 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 11 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 2 trial is estimated to last approximately 2 years and 1 month.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.